THE INFLUENCE OF METRONIDAZOLE ON THE PHARMACOKINETIC PROFILE OF CHLORPROPAMIDE IN TYPE II DIABETIC PATIENTS

dc.contributor.authorBELLO, KUDIRAT
dc.date.accessioned2014-02-21T10:07:14Z
dc.date.available2014-02-21T10:07:14Z
dc.date.issued1998-09
dc.descriptionA THESIS SUBMITTED TO THE POSTGRADUATE SCHOOL, AHMADU BELLO UNIVERSITY, ZARIA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF MASTER DEGREE DEPARTMENT OF PHARMACEUTICAL AND MEDICINAL CHEMISTRY, FACULTY OF PHARMACEUTICAL SCIENCES, AHMADU BELLO UNIVERSITY, ZARIAen_US
dc.description.abstractThe influence of metronidazole on the pharmacokinetic profile of chlorpropamide in Type II diabetic patients was examined. The quality of chlorpropamide and metronidazole tablets used in the study were pre -determined using official methods. The tablets complied with the BP (1988) requirements stated under the monograph for chlorpropamide and metronidazole tablets. Plasma levels of chlorpropamide were determined using colorimctric method (Martin et al, 1973). In addition, glucose levels were measured by standard glucose oxidase method (Martinek, 1964). Decreased levels of chlorpropamide were observed in concomitant administration of 250mg chlorpropamide with two 200mg metronidazole tablets(C) compared with administration of 250mg chlorpropamide tablet (control) (B). Insignificantly higher (pre and postprandial) levels of plasma glucose were observed in concomitant administration of metronidazole with chlorpropamide compared with administration of 250mg chlorpropamide alone. The pharmacokinetic parameters were calculated using semi - logarimathmic plots of concentration- time data for chlorpropamide. The area under the curve was calculated by trapezoidal rule. Administration of metronidazole concomitantly with chlorpropamide significantly affected some pharmacokinetic parameters of chlorpropamide such as ka, Cmax, Vd, AUG, and ti/2Ct. The elimination parameters, Lag time, and tmax as calculated in this study were not significantly affected.en_US
dc.identifier.urihttp://hdl.handle.net/123456789/2284
dc.language.isoenen_US
dc.subjectINFLUENCE,en_US
dc.subjectMETRONIDAZOLE,en_US
dc.subjectPHARMACOKINETIC,en_US
dc.subjectPROFILE,en_US
dc.subjectCHLORPROPAMIDE,en_US
dc.subjectTYPE II,en_US
dc.subjectDIABETIC,en_US
dc.subjectPATIENTS.en_US
dc.titleTHE INFLUENCE OF METRONIDAZOLE ON THE PHARMACOKINETIC PROFILE OF CHLORPROPAMIDE IN TYPE II DIABETIC PATIENTSen_US
dc.typeThesisen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
KUDIRAT BELLO.pdf
Size:
2.96 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.58 KB
Format:
Item-specific license agreed upon to submission
Description: